» Articles » PMID: 6115110

Transplantation for Acute Leukaemia with HLA-A and B Nonidentical Parental Marrow Cells Fractionated with Soybean Agglutinin and Sheep Red Blood Cells

Overview
Journal Lancet
Publisher Elsevier
Specialty General Medicine
Date 1981 Aug 15
PMID 6115110
Citations 73
Authors
Affiliations
Soon will be listed here.
Abstract

A new procedure for enrichment of marrow precursors and removal of T lymphocytes from large volumes of human bone marrow, involving initial differential agglutination of T lymphocytes and mature marrow elements with soybean agglutinin, followed by rosetting with sheep red blood cells, was used to fractionate marrow cells from an HLA-A, B, DR non-identical, MLC non-reactive, paternal donor for transplantation into an infant with acute leukaemia. This transplant became completely engrafted and resulted in full recovery of normal, donor-derived haematopoietic function without graft-versus-host disease, sustained for 11 weeks after transplantation, at which time the patient's leukaemia recurred. Subsequently, the patient received chemotherapy and achieved a remission with regeneration of normal marrow cells of donor origin. The patient's course demonstrated the potential of lectin-separated marrow grafts to restore durable haematopoiesis, without graft versus host disease, in a lethally irradiated allogeneic host.

Citing Articles

Deciphering the Complexities of Adult Human Steady State and Stress-Induced Hematopoiesis: Progress and Challenges.

Watt S, Roubelakis M Int J Mol Sci. 2025; 26(2).

PMID: 39859383 PMC: 11766050. DOI: 10.3390/ijms26020671.


Janus kinase inhibition in the treatment and prevention of graft-versus-host disease.

De Togni E, Cole O, Abboud R Front Immunol. 2024; 15:1304065.

PMID: 38380328 PMC: 10877010. DOI: 10.3389/fimmu.2024.1304065.


Allogeneic hematopoietic stem cell transplantation to cure sickle cell disease: A review.

Bhalla N, Bhargav A, Yadav S, Singh A Front Med (Lausanne). 2023; 10:1036939.

PMID: 36910492 PMC: 9995916. DOI: 10.3389/fmed.2023.1036939.


Immune Reconstitution After Allogeneic Haematopoietic Cell Transplantation: From Observational Studies to Targeted Interventions.

Yanir A, Schulz A, Lawitschka A, Nierkens S, Eyrich M Front Pediatr. 2022; 9:786017.

PMID: 35087775 PMC: 8789272. DOI: 10.3389/fped.2021.786017.


Advances in Allogeneic Cancer Cell Therapy and Future Perspectives on "Off-the-Shelf" T Cell Therapy Using iPSC Technology and Gene Editing.

Furukawa Y, Hamano Y, Shirane S, Kinoshita S, Azusawa Y, Ando J Cells. 2022; 11(2).

PMID: 35053386 PMC: 8773622. DOI: 10.3390/cells11020269.